Case Study of Acquired Resistance to FGFR Inhibition in Cholangiocarcinoma
Demographics (1)
- SEX - Self-reported sex (phv00420455.v1.p1)
Disease Events (1)
- AFFECTION_STATUS - Case control status of the subject for cholangiocarcinoma (phv00420454.v1.p1)
Other (13)
- ACQUISITION_TYPE - Whether the sample was collected during a biopsy or is ctDNA (phv00420463.v1.p1)
- ANALYTE_TYPE - Analyte type (phv00420458.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00420457.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00420450.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00420460.v1.p1)
- IS_TUMOR - Tumor status (phv00420459.v1.p1)
- SAMPLE_ID - Sample ID (phv00420456.v1.p1)
- SAMPLE_ID - Sample ID (phv00420452.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00420462.v1.p1)
- SUBJECT_ID - Subject ID (phv00420453.v1.p1)
- SUBJECT_ID - Subject ID (phv00420449.v1.p1)
- SUBJECT_ID - Subject ID (phv00420451.v1.p1)
- TREATMENT - Whether the sample is pre-infigratinib treatment, post-infigratinib treatment, or post-irinotecan progression (phv00420461.v1.p1)